This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About ISENTRESS® 400 mg (raltegravir)

Updated on 15/03/2018

HIV
Start and stay on an ARV today for their tomorrow

ISENTRESS 400 mg is a twice daily integrase strand transfer inhibitor

ISENTRESS 400 mg has been studied across a broad range of treatment–naïve populations2-7


  • ISENTRESS 400 mg has demonstrated durable efficacy through to 240 weeks2
  • A favourable long term safety profile with few discontinuations2
  • A low incidence of drug-drug interactions1,8
    • Allows for concomitant use with a wide range of non-ARVs
  • Over 7 years of clinical experience in the UK
  • ISENTRESS 400 mg is indicated for use in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, children, toddlers and infants from the age of 4 weeks1

References

  1. ISENTRESS Summary of Product Characteristics.
  2. Rockstroh JK, De Jesus E, Saag M et al. Durable Efficacy and Safety Of Raltegravir Versus Efavirenz when combined with Tenofovir/Emtricitabine in Treatment Naive HIV Infected Patients: Final 5-Year Results from STARTMRK J Acquir Immune Defic Syndr. 2013 May 1;63(1):77 85.
  3. Gotuzzo E et al. Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection: Final Results of a Randomized, Controlled, Phase II Study (Protocol 004). Supplement J Acquir Immune Defic Syndr 2012;61:73–77.
  4. Lennox J, Landowitz R et al. Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor- Sparing Antriretroviral Regimens for Treatment Naive volunteers Infected with HIV-1. Ann Intern Med 2014;161:461-471.
  5. Raffi F et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013; 13: 927–35.
  6. Young B et al. 0930HIV_96-Week Results of a Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: The SHIELD Trial HIV Clin Trials. 2011;12: 228-233.
  7. Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. The Lancet, August 5, 2014.
  8. University of Liverpool Drug Interactions website www.hiv-druginteractions.org, Accessed February 2016.

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

INFC-1246443-0000 | Date of Preparation: March 2018